Compare ECF & MXCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ECF | MXCT |
|---|---|---|
| Founded | 1986 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 162.7M | 136.2M |
| IPO Year | N/A | 2021 |
| Metric | ECF | MXCT |
|---|---|---|
| Price | $11.75 | $1.24 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $4.11 |
| AVG Volume (30 Days) | 44.5K | ★ 316.9K |
| Earning Date | 01-01-0001 | 11-04-2026 |
| Dividend Yield | ★ 6.42% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.46 | N/A |
| Revenue | N/A | ★ $33,026,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $18.24 |
| P/E Ratio | $26.09 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $10.71 | $0.64 |
| 52 Week High | $13.85 | $1.86 |
| Indicator | ECF | MXCT |
|---|---|---|
| Relative Strength Index (RSI) | 37.77 | 61.43 |
| Support Level | $11.16 | $1.19 |
| Resistance Level | $12.68 | $1.27 |
| Average True Range (ATR) | 0.18 | 0.06 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 11.20 | 83.50 |
Ellsworth Growth and Income Fund Ltd operate as a closed-end, diversified management investment company. Its investment objective is to provide income and the potential for capital appreciation, which objectives the Fund considers to be relatively equal over the long term due to the nature of the securities in which it invests. The company invests in convertible and equity securities. It invests in various sectors, such as healthcare, financial services, computer software and services, energy and utilities, real estate investment trusts, semiconductors, telecommunications, business services, food and beverage, consumer products, transportation, consumer services among others.
MaxCyte Inc is a life sciences company focused on advancing the discovery, development, and commercialization of next-generation cell therapies. It uses its proprietary cell engineering technology platform to support biotechnology and pharmaceutical customers in cell therapy, gene editing, immuno-oncology, and biologic development. It operates in one segment: cell engineering technology, which generates revenue mainly from product sales, licenses, research and clinical license fees, and program-related revenues as its SPL customers achieve development and regulatory milestones. Its platform, the ExPERT Platform, is based on Flow Electroporation technology designed to efficiently and safely modify human cells with high efficiency, low cytotoxicity, and scalability for clinical use.